BDRX Biodexa Pharmaceuticals Plc - Fundamental Analysis
BEARISH
Sign in to save
Save to watchlist or track a position.
BDRX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.15
52W High
$92.0
52W Low
$2.03
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.8M
P/E
N/A
ROE
-61.8%
Profit margin
N/A
Debt/Equity
0.04
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.
Key Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Average earnings surprise of +30.78% in recent quarters, suggesting possible undervaluation or improving efficiency.
Price/Sales and EV/Revenue metrics are not available, leaving room for potential undervaluation if revenue emerges.
Key Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.
Market cap and enterprise value are listed as $0.00B and N/A, indicating possible delisting or shell-status risk.
Stock has declined 95.1% over the past year and 100% over 3 and 5 years, signaling severe loss of investor confidence.
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
10
Weak
10
20
10
10
0
AI Verdict
Extremely high-risk investment with no current profitability, undefined valuation, and deteriorating market performance.
Key drivers: Piotroski F-Score of 2/9, Negative ROE and ROA, Lack of revenue and earnings growth data, 100% decline over 5 years, No analyst coverage
Confidence
95%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book ratio of 0.09 suggests potential asset-based undervaluation
Watchpoints
- No P/E, Forward P/E, PEG, or Graham Number due to lack of earnings
- No meaningful revenue or EBITDA for valuation
Future
20/100
Ref Growth rates
Positives
- Two recent earnings beats and positive average surprise
Watchpoints
- No YoY or Q/Q growth data available
- No forward guidance or analyst targets
Past
10/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5Y, 3Y, and 1Y price changes of -100%, -100%, and -95.1% respectively
- No historical revenue or earnings progression available
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios above 3.6 indicate strong short-term liquidity
Watchpoints
- Piotroski F-Score of 2/9 indicates weak financial health
- ROE of -61.77% and ROA of -39.04% reflect severe unprofitability
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield, payout, or history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.15
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BDRX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
Primary
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.8% | -67.1% | -51.2% |
|
ACON
Aclarion, Inc.
Peer
|
-100.0% | -100.0% | -82.0% | -56.9% | +22.9% | +1.8% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.09
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
-15012.8
Market Cap
$1.8M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
N/A
Gross Margin
N/A
ROE
-61.77%
ROA
-39.04%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.04
Low debt
Current Ratio
3.63
Strong
Quick Ratio
3.63
Excellent
Cash/Share
$N/A
Quarterly Earnings History
EPS performance vs analyst estimates
2020-09-09
$-8800.0
+78.0% surprise
2020-09-09
$-8800.0
+56.0% surprise
2020-06-14
$-1700000.0
-41.7% surprise
Healthcare Sector Comparison
Comparing BDRX against 147 companies in the Healthcare sector
(11 bullish, 53 neutral, 83 bearish)
Return on Equity (ROE)
-61.77%
This Stock
vs
-54.98%
Sector Avg
+12.3%
(Excellent)
Debt to Equity
0.04
This Stock
vs
6.16
Sector Avg
-99.3%
(Less Debt)
Current Ratio
3.63
This Stock
vs
3.39
Sector Avg
+7.1%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | |
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.4M | - | -% | -% | $1.82 | |
|
ACON
Aclarion, Inc.
|
BEARISH | $3.51M | - | -97.7% | -% | $3.33 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 |
Past News Coverage
Recent headlines mentioning BDRX from our newsroom.
Newest → oldest
No matching news yet.